Legis Daily

RAISE Act

USA116th CongressHR-8177| House 
| Updated: 9/4/2020
Tom O'Halleran

Tom O'Halleran

Democratic Representative

Arizona

Cosponsors (3)
Markwayne Mullin (Republican)G. K. Butterfield (Democratic)Larry Bucshon (Republican)

Ways and Means Committee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Renal Anemia Innovation Support and Expansion Act or the RAISE Act This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Sep 19, 2019

Latest Companion Bill Action

S 116-2510
Introduced in Senate
Sep 4, 2020
Introduced in House
Sep 4, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • September 19, 2019

    Latest Companion Bill Action

    S 116-2510
    Introduced in Senate


  • September 4, 2020
    Introduced in House


  • September 4, 2020
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Health

Blood and blood diseasesDigestive and metabolic diseasesHealth care coverage and accessMedicarePrescription drugs

RAISE Act

USA116th CongressHR-8177| House 
| Updated: 9/4/2020
Renal Anemia Innovation Support and Expansion Act or the RAISE Act This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Sep 19, 2019

Latest Companion Bill Action

S 116-2510
Introduced in Senate
Sep 4, 2020
Introduced in House
Sep 4, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • September 19, 2019

    Latest Companion Bill Action

    S 116-2510
    Introduced in Senate


  • September 4, 2020
    Introduced in House


  • September 4, 2020
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Tom O'Halleran

Tom O'Halleran

Democratic Representative

Arizona

Cosponsors (3)
Markwayne Mullin (Republican)G. K. Butterfield (Democratic)Larry Bucshon (Republican)

Ways and Means Committee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Blood and blood diseasesDigestive and metabolic diseasesHealth care coverage and accessMedicarePrescription drugs